ALK-Abello A/S
https://www.alk.net/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ALK-Abello A/S
Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.
Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
Company Information
- Industry
- In Vitro Diagnostics
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- ALK-Abelló
- Allergy Laboratories, Inc.
- Crystal Laboratory LLC